Galmed Pharmaceuticals (GLMD) Non Operating Investment Income (2015 - 2022)
Galmed Pharmaceuticals (GLMD) posted quarterly Non Operating Investment Income of $229000.0 for Q3 2022, up 1861.54% year-over-year from $11674.5 in Q3 2021, and up 1861.54% quarter-over-quarter from -$13000.0 in Q3 2021.
Galmed Pharmaceuticals (GLMD) Non Operating Investment Income (2015 - 2022) Analysis & Trends
Galmed Pharmaceuticals' Non Operating Investment Income history runs 8 years deep, the most recent figure standing at $229000.0 for Q3 2022.
- In Q3 2022, Non Operating Investment Income rose 1861.54% year-over-year to $229000.0; the TTM figure through Sep 2022 stood at $197000.0 (up 136.21% YoY), while the FY2018 annual figure was $12000.0, down 91.61% from the prior year.
- Non Operating Investment Income for Q3 2022 stood at $229000.0, up from -$13000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $229000.0 in Q3 2022, with the low at -$512000.0 in Q3 2020.
- The 5-year median for Non Operating Investment Income is -$1000.0 (2018), against an average of -$23071.4.
- The sharpest annual moves came in 2020 and 2022: Non Operating Investment Income plunged 51100.0% in 2020, then surged 1861.54% in 2022.
- Galmed Pharmaceuticals' Non Operating Investment Income stood at -$1000.0 in 2018, then changed by 0.0% to -$1000.0 in 2019, then slumped by 51100.0% to -$512000.0 in 2020, then soared by 97.46% to -$13000.0 in 2021, then soared by 1861.54% to $229000.0 in 2022.
- Business Quant data shows GLMD's Non Operating Investment Income at $229000.0 in Q3 2022, -$13000.0 in Q3 2021, and -$34000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 229,000.00 |
| Sep 30, 2022 | 229,000.00 |
| Sep 30, 2021 | -13,000.00 |
| Sep 30, 2021 | -13,000.00 |
| Jun 30, 2021 | -34,000.00 |
| Jun 30, 2021 | -34,000.00 |
| Mar 31, 2021 | 15,000.00 |
| Mar 31, 2021 | 15,000.00 |
| Sep 30, 2020 | -512,000.00 |
| Sep 30, 2020 | -512,000.00 |
| Jun 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 1,000.00 |
| Mar 31, 2020 | -11,000.00 |
| Mar 31, 2020 | -11,000.00 |
| Sep 30, 2019 | -1,000.00 |
| Sep 30, 2019 | -1,000.00 |
| Jun 30, 2019 | -4,000.00 |
| Jun 30, 2019 | -4,000.00 |
| Mar 31, 2019 | -5,000.00 |
| Mar 31, 2019 | -5,000.00 |